BioStock: Immunicum gears up for second half of 2020
2020 has so far been a transition year for Immunicum. While continuing their progress with the Phase II MERECA study and Phase Ib/II ILIAD study, they have received RMAT designation from the FDA for their top drug candidate ilixadencel. Recently, the immuno-oncology company also received feedback from both the FDA and EMA to further support preparations of the next steps in development. BioStock spoke with Immunicum’s Interim CEO Alex Karlsson-Parra to look back at the year so far and see what is in the books for the rest of the year.Read the full interview with Alex Karlsson-Parra at